Literature DB >> 10352103

The role of the plasminogen system in bone resorption in vitro.

E Daci1, N Udagawa, T J Martin, R Bouillon, G Carmeliet.   

Abstract

The plasminogen/plasmin proteolytic cascade plays an important role in extracellular matrix remodeling. The presence of the two plasminogen activators (PAs), tissue-type plasminogen activator (tPA), and urokinase-type plasminogen activator (uPA), and their inhibitor type 1 (PAI-1) in bone cells, suggests a role in one or more aspects of bone resorption such as osteoclast formation, mineral dissolution, and degradation of the organic matrix. These different processes were assayed in vitro using cells derived from mice with either tPA (tPA-/-), uPA (uPA-/-), PAI-1 (PAI-1-/-) inactivation or with a combined inactivation (tPA-/-:uPA-/-) and compared with wild-type mice (WT). First, osteoclast formation, assessed by investigating the number and characteristics of tartrate-resistant acid phosphatase-positive multinucleated cells formed in cocultures of primary osteoblasts and bone marrow cells treated with 1alpha,25-dihydroxyvitamin D3, was not different between the different cell types. Second, dentine resorption, an assay for osteoclast activity, was not affected by the combined deficiency of both tPA and uPA. Finally, the ability to degrade nonmineralized bone-like matrix was however, significantly reduced in tPA-/-:uPA-/- cells compared with WT cells (28.1 +/- 0.6%, n = 6 vs. 56.4 +/- 3.1%, n = 6, respectively, p < 0.0001). Surprisingly, collagen proteolysis by bone cells was not dependent on the presence of plasmin as suggested by degradation assays performed on type I 3H-collagen films. Taken together, these data suggest that the plasminogen activator/plasmin system is not required for osteoclast formation, nor for the resorption of the mineral phase, but is involved in the removal of noncollagenous proteins present in the nonmineralized bone matrix.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10352103     DOI: 10.1359/jbmr.1999.14.6.946

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  16 in total

1.  Plasminogen/plasmin modulates bone metabolism by regulating the osteoblast and osteoclast function.

Authors:  Yosuke Kanno; Akira Ishisaki; Eri Kawashita; Naoyuki Chosa; Keiichi Nakajima; Tatsuji Nishihara; Kuniaki Toyoshima; Kiyotaka Okada; Shigeru Ueshima; Kenji Matsushita; Osamu Matsuo; Hiroyuki Matsuno
Journal:  J Biol Chem       Date:  2011-01-14       Impact factor: 5.157

2.  Analysis of soluble urokinase plasminogen activator receptor in multiple myeloma for predicting prognosis.

Authors:  Jie Shen; Qing Wang; Juan Wang; Guo-Hong Su; Juan Wang; Sheng-Hu Guo; Y A Liu; Zheng Wu; Rong-Feng Liu; Xing Li; Xiao-Jin Guo; Jing Cao; Yue-Hua Zhang; Zhi-Yu Wang
Journal:  Oncol Lett       Date:  2015-08-14       Impact factor: 2.967

3.  Recombinant Human Plasminogen Activator Inhibitor-1 Promotes Cementogenic Differentiation of Human Periodontal Ligament Stem Cells.

Authors:  Hexiu Jin; Han-Wool Choung; Ki-Taek Lim; Bin Jin; Chengbiao Jin; Jong-Hoon Chung; Pill-Hoon Choung
Journal:  Tissue Eng Part A       Date:  2015-08-14       Impact factor: 3.845

4.  Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts.

Authors:  Ritsuko Masuyama; Ingrid Stockmans; Sophie Torrekens; Riet Van Looveren; Christa Maes; Peter Carmeliet; Roger Bouillon; Geert Carmeliet
Journal:  J Clin Invest       Date:  2006-11-09       Impact factor: 14.808

5.  1,25-dihydroxyvitamin D3 influences cellular homocysteine levels in murine preosteoblastic MC3T3-E1 cells by direct regulation of cystathionine β-synthase.

Authors:  Carsten Kriebitzsch; Lieve Verlinden; Guy Eelen; Natasja M van Schoor; Karin Swart; Paul Lips; Mark B Meyer; J Wesley Pike; Steven Boonen; Carsten Carlberg; Victor Vitvitsky; Roger Bouillon; Ruma Banerjee; Annemieke Verstuyf
Journal:  J Bone Miner Res       Date:  2011-12       Impact factor: 6.741

6.  Placental growth factor mediates mesenchymal cell development, cartilage turnover, and bone remodeling during fracture repair.

Authors:  Christa Maes; Lieve Coenegrachts; Ingrid Stockmans; Evis Daci; Aernout Luttun; Anna Petryk; Rajaram Gopalakrishnan; Karen Moermans; Nico Smets; Catherine M Verfaillie; Peter Carmeliet; Roger Bouillon; Geert Carmeliet
Journal:  J Clin Invest       Date:  2006-04-13       Impact factor: 14.808

7.  Fibrinolysis is essential for fracture repair and prevention of heterotopic ossification.

Authors:  Masato Yuasa; Nicholas A Mignemi; Jeffry S Nyman; Craig L Duvall; Herbert S Schwartz; Atsushi Okawa; Toshitaka Yoshii; Gourab Bhattacharjee; Chenguang Zhao; Jesse E Bible; William T Obremskey; Matthew J Flick; Jay L Degen; Joey V Barnett; Justin M M Cates; Jonathan G Schoenecker
Journal:  J Clin Invest       Date:  2015-07-27       Impact factor: 14.808

8.  Transgenic over-expression of plasminogen activator inhibitor-1 results in age-dependent and gender-specific increases in bone strength and mineralization.

Authors:  S M Nordstrom; S M Carleton; W L Carson; M Eren; C L Phillips; D E Vaughan
Journal:  Bone       Date:  2007-08-17       Impact factor: 4.398

9.  Differentially expressed genes in autosomal dominant osteopetrosis type II osteoclasts reveal known and novel pathways for osteoclast biology.

Authors:  Amélie E Coudert; Andrea Del Fattore; Céline Baulard; Robert Olaso; Corinne Schiltz; Corinne Collet; Anna Teti; Marie-Christine de Vernejoul
Journal:  Lab Invest       Date:  2013-12-16       Impact factor: 5.662

10.  Class 3 semaphorins are transcriptionally regulated by 1,25(OH)2D3 in osteoblasts.

Authors:  Jussi Ryynänen; Carsten Kriebitzsch; Mark B Meyer; Iris Janssens; J Wesley Pike; Lieve Verlinden; Annemieke Verstuyf
Journal:  J Steroid Biochem Mol Biol       Date:  2017-02-09       Impact factor: 5.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.